Authors

  • Duncan Emerton

DOI:

https://doi.org/10.5912/jcb195

Keywords:

LDL-C, HDL-C, CETP inhibitor, Apo-A1 mimetics, vaccine

Abstract

In this current analysis of the antidyslipidaemics market, a shift in focus from low-density lipoprotein cholesterol (LDL-C)-targeted therapies to drugs that elevate high-density lipoprotein cholesterol (HDL-C) is described. Key reasons for this evolution are several-fold, but mainly focus on significant generic erosion of LDL-C-targeted therapies, particularly the statins, and loss of revenues therein. Additionally, with LDL-C-lowering efficacy unlikely to improve without sacrificing patient safety, elevating HDL-C has emerged as a therapeutic option in the long-running battle against coronary heart disease.

Downloads